WO2020191229A1 - Capsules and capsule coatings for gastric residence dosage forms - Google Patents

Capsules and capsule coatings for gastric residence dosage forms Download PDF

Info

Publication number
WO2020191229A1
WO2020191229A1 PCT/US2020/023704 US2020023704W WO2020191229A1 WO 2020191229 A1 WO2020191229 A1 WO 2020191229A1 US 2020023704 W US2020023704 W US 2020023704W WO 2020191229 A1 WO2020191229 A1 WO 2020191229A1
Authority
WO
WIPO (PCT)
Prior art keywords
gastric residence
dosage form
coating
less
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/023704
Other languages
English (en)
French (fr)
Inventor
Nupura BHISE
David Altreuter
Erick PEEKE
Marlene Schwarz
Megan BISHOFF
Sonia HOLAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lyndra Therapeutics Inc
Original Assignee
Lyndra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2021011314A priority Critical patent/MX2021011314A/es
Priority to JP2021556484A priority patent/JP2022525926A/ja
Priority to EP20774505.0A priority patent/EP3941445A4/en
Priority to BR112021018496A priority patent/BR112021018496A2/pt
Priority to US17/593,436 priority patent/US12447130B2/en
Priority to CN202411107403.6A priority patent/CN119033720A/zh
Priority to IL286512A priority patent/IL286512B2/en
Priority to CA3134049A priority patent/CA3134049A1/en
Priority to CN202080034334.4A priority patent/CN113966216A/zh
Priority to AU2020240108A priority patent/AU2020240108B2/en
Application filed by Lyndra Therapeutics Inc filed Critical Lyndra Therapeutics Inc
Publication of WO2020191229A1 publication Critical patent/WO2020191229A1/en
Priority to MX2025012985A priority patent/MX2025012985A/es
Anticipated expiration legal-status Critical
Priority to JP2025005892A priority patent/JP2025066761A/ja
Priority to US19/262,609 priority patent/US20250332111A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Definitions

  • Gastric residence systems are delivery systems for therapeutic agents that can remain in the stomach for days to weeks, or even over longer periods, during which time the therapeutic agent can elute from the gastric residence system for absorption in the gastrointestinal tract.
  • Gastric residence systems are typically designed to be administered in a capsule to reach the stomach of a patient.
  • the encapsulated gastric residence system is swallowed or introduced into the stomach by an alternate method of administration (e.g., feeding tube or gastric tube).
  • the gastric residence system Upon dissolution of the capsule in the stomach, the gastric residence system expands or unfolds to a size which remains in the stomach and resists passage through the pyloric valve over the desired residence period (such as three days, seven days, two weeks, etc.).
  • capsules and capsule coatings for gastric residence systems are also provided.
  • methods of preparing a gastric residence dosage form using the capsules and/or capsule coatings provided herein can ensure that the gastric residence system unfolds at a predetermined time and location within the gastrointestinal tract (i.e., in the stomach).
  • capsules and capsule coatings provided can minimize the risk of the gastric residence system unfolding too early (e.g., in the esophagus) and causing an obstruction.
  • Capsules and capsule coatings described herein may also minimize the possibility of the gastric residence system passing through the stomach and unfolding later in the gastrointestinal tract (i.e., intestine).
  • Capsules and capsule coatings provided herein minimize the risk of a gastric residence dosage form passing through the gastrointestinal tract without unfolding at all. In each of these possible scenarios, the therapeutic agent is not delivered to the patient as intended.
  • Capsules and capsule coatings provided herein may include a sleeve or band used to bind the gastric residence system in a folded configuration.
  • a bound gastric residence system may be encapsulated with a capsule to form a gastric residence dosage form.
  • Some gastric residence dosage forms may include a reverse-enteric coating to ensure dissolution of the capsule in a gastric environment, and not prior to the gastric environment, such that the gastric residence system unfolds and assumes an open configuration within the stomach as intended.
  • methods for preparing a gastric residence dosage form as provided herein can include binding a folded gastric residence system with a sleeve and encapsulating the bound gastric residence system with a capsule.
  • methods for preparing a gastric residence dosage form may also include coating the encapsulated gastric residence system with a reverse-enteric coating to ensure dissolution of the capsule and delivery of the gastric residence system within the stomach of a patient.
  • the gastric residence dosage form allows the gastric residence system to assume the open configuration in a first amount of time when exposed to an aqueous pH 7.0 environment, and the first amount of time is greater than a second amount of time for an uncoated gastric residence dosage form comprising an uncoated capsule to allow a gastric residence system to assume an open configuration when the uncoated gastric residence dosage form is exposed to the aqueous pH 7.0 environment.
  • the first amount of time is at least 1 minute greater than the second amount of time.
  • the gastric residence dosage form allows the gastric residence system to assume the open configuration in less than 30 minutes when exposed to the aqueous pH 3.0 environment. [0015] In some embodiments of the gastric residence dosage form, the gastric residence dosage form allows the gastric residence system to assume the open configuration in less than 15 minutes when exposed to the aqueous pH 3.0 environment. [0016] In some embodiments of the gastric residence dosage form, the gastric residence dosage form comprises a sleeve, wherein the sleeve surrounds at least a portion of the gastric residence system in the folded configuration. [0017] In some embodiments of the gastric residence dosage form, the coating comprises a reverse-enteric polymer.
  • the plasticizer comprises at least one of a phthalate, a phosphate, a citrate, a tartrate, an adipate, a sebacate, a sulfonamide, a succinate, a glycolate, a glycerolate, a benzoate, a myristate, a polyethylene glycol, a halogenated phenyl, or a poloxamer.
  • the plasticizer comprises at least one of triacetin or dibutyl sebacate.
  • the coating comprises a hydration aid.
  • the hydration aid comprises at least one of a polyvinylpyrrolidone, a vinylpyrrolidone-vinyl acetate copolymer, a polyethylene glycol, mannitol, or hydroxypropyl methylcellulose.
  • the coating comprises from 50 to 95 wt. % reverse-enteric polymer.
  • the coating comprises from 3 to 25 wt. % anti-tacking agent.
  • the coating comprises from 1 to 20 wt. % plasticizer.
  • a coating for an encapsulated gastric residence system comprising: 50-95 wt. % reverse-enteric polymer; 3-25 wt. % anti- tacking agent; and 1-20 wt. % plasticizer.
  • the coating is on a surface of a capsule, forming a coated capsule.
  • the coated capsule encapsulates a gastric residence system to form a gastric residence dosage form, wherein the gastric residence dosage form is configured to release the gastric residence system in a stomach of a patient, allowing the gastric residence system to assume an open configuration.
  • the coating comprises 5 to 35 wt. % hydration aid.
  • the hydration aid comprises at least one of a polyvinylpyrrolidone, a vinylpyrrolidone-vinyl acetate copolymer, a polyethylene glycol, mannitol, or hydroxypropyl methylcellulose.
  • the reverse-enteric polymer comprises a polymethacrylate-based polymer.
  • the anti-tacking agent comprises at least one of talc or magnesium stearate.
  • the plasticizer comprises a phthalate, a phosphate a citrate a tartrate an adipate a sebacate a sulfonamide a succinate a glycolate a glycerolate, a benzoate, a myristate, a polyethylene glycol, a halogenated phenyl, or a poloxamer.
  • the plasticizer comprises at least one of triacetin and dibutyl sebacate.
  • the coating is soluble in an aqueous solution.
  • the coating is soluble in an organic solution.
  • the gastric residence dosage form allows the gastric residence system to assume the open configuration in a first amount of time when exposed to an aqueous pH 7.0 environment, and the first amount of time is greater than a second amount of time for an uncoated gastric residence dosage form comprising an uncoated capsule to allow a gastric residence system to assume an open configuration when the uncoated gastric residence dosage form is exposed to the aqueous pH 7.0 environment.
  • the first amount of time is at least 1 minute greater than the second amount of time.
  • the gastric residence dosage form allows the gastric residence system to assume the open configuration in less than 30 minutes when exposed to the aqueous pH 3.0 environment.
  • the gastric residence dosage form allows the gastric residence system to assume the open configuration in less than 15 minutes when exposed to the aqueous pH 3.0 environment.
  • a gastric residence dosage form is provided, wherein the gastric residence dosage form comprises a coating according to one or more embodiments provided herein, and the gastric residence dosage form is used to treat a patient.
  • the patient is a human.
  • the anti-tacking agent comprises at least one of talc or magnesium stearate.
  • the plasticizer comprises at least one of a phthalate, a phosphate, a citrate, a tartrate, an adipate, a sebacate, a sulfonamide, a succinate, a glycolate, a glycerolate, a benzoate, a myristate, a polyethylene glycol, a halogenated phenyl, or a poloxamer.
  • the sleeve comprises at least one of gelatin, hydroxypropyl methylcellulose, or pullulan.
  • the gastric residence dosage form is configured to release the gastric residence system in a stomach of a patient, allowing the gastric residence system to assume an open configuration.
  • the gastric residence dosage form allows the gastric residence system to assume the open configuration in a third amount of time when exposed to an aqueous pH 3.0 environment, and the third amount of time is greater than a fourth amount of time for an uncoated gastric residence dosage form comprising an uncoated capsule to allow a gastric residence system to assume an open configuration when the uncoated gastric residence dosage form is exposed to the aqueous pH 3.0 environment.
  • the third amount of time is at least 15 seconds greater than the fourth amount of time.
  • the gastric residence dosage form allows the gastric residence system to assume the open configuration in less than 30 minutes when exposed to the aqueous pH 3.0 environment. [0074] In some embodiments of the method, the gastric residence dosage form allows the gastric residence system to assume the open configuration in less than 15 minutes when exposed to the aqueous pH 3.0 environment. [0075] In some embodiments, a gastric residence dosage form made using the method of any embodiments provided herein, wherein the gastric residence dosage form is used to treat a patient. [0076] In some embodiments of the gastric residence dosage form, the patient is a human. [0077] In some embodiments, a coated dosage form is provided, the coated dosage form comprising: a dosage form; and a coating comprising a reverse-enteric polymer coating the dosage form, wherein
  • the coating comprises magnesium stearate.
  • the dosage form comprises one of a tablet, a capsule, or an enrobed gastric residence system.
  • the dosage form comprises a capsule.
  • the capsule encapsulates a gastric residence system.
  • the static coefficient of friction of the coated dosage form is less than 0.3.
  • the static coefficient of friction of the coated dosage form is less than 0.1.
  • the static coefficient of friction is at least 0.08 less than that of an uncoated dosage form.
  • the reverse-enteric polymer comprises a polymethacrylate.
  • the coating comprises an anti- tacking agent.
  • the anti-tacking agent comprises talc.
  • the coating comprises 5 to 30 wt. % anti-tacking agent.
  • Fig.1A shows a gastric residence system in an open configuration, according to some embodiments
  • Fig.1B shows a gastric residence system in an open configuration, according to some embodiments
  • Fig.1C shows a gastric residence system in an open configuration, according to some embodiments
  • FIG.3A shows a folded gastric residence system and a sleeve, according to some embodiments
  • FIG.3B shows a sleeved gastric residence system, according to some embodiments.
  • Fig.3C shows a sleeved gastric residence system and a body portion of a two-piece capsule, according to some embodiments
  • Fig.3D shows a sleeved gastric residence system placed inside a body portion of a two-piece capsule, and a cap portion of a two-piece capsule, according to some embodiments;
  • Fig.4D shows a sleeved gastric residence system placed inside a body portion of a two-piece capsule, and a cap portion of a two-piece capsule, according to some embodiments;
  • Fig.5A shows a folded gastric residence system sleeved on a core side, according to some embodiments;
  • Fig.5B shows an encapsulated and sleeved folded gastric residence system, according to some embodiments;
  • Fig.5C shows an encapsulated and sleeved folded gastric residence system, according to some embodiments;
  • Fig.6A shows a folded gastric residence system, according to some embodiments;
  • Fig.6B shows a sleeved gastric residence system, according to some embodiments;
  • Fig.6C shows an encapsulated gastric residence system, according to some embodiments;
  • Fig.6D shows a coated encapsulated gas
  • capsules and capsule coatings for gastric residence systems are designed to be administered to a patient when the gastric residence system is in a folded or collapsed configuration (i.e., to enable swallowing and easy passage of the drug delivery device to the patient’s stomach).
  • gastric residence system When the gastric residence system enters the patient’s stomach, it unfolds system results in a dosage form with effective size (i.e., a gastric residence system in an open configuration) that is too large to pass through the patient’s pyloric valve (i.e., opening between the stomach and the large intestine).
  • the deployed, or expanded, gastric residence system can stay in the patient’s stomach for a predetermined period of time (e.g., 24 hours, 48 hours, 7 days, 10 days, etc.).
  • a predetermined period of time e.g., 24 hours, 48 hours, 7 days, 10 days, etc.
  • one challenge in particular with gastric residence systems is controlling their opening/unfolding.
  • a gastric residence system that unfolds too early (e.g., in a patient’s esophagus) or too late (e.g., in a patient’s intestine) is undesirable.
  • a gastric residence system that fails to unfold at all may pass completely through a patient’s gastrointestinal tract still in a folded configuration. In each of these hypothetical situations, the gastric residence system fails to properly deliver its therapeutic agent (e.g., active pharmaceutical ingredient) to the patient’s stomach.
  • its therapeutic agent e.g., active pharmaceutical ingredient
  • the particular capsule and/or capsule coating used to prepare the gastric residence dosage form can be specially formulated to ensure that the gastric residence system does not deploy too early (e.g., in a patient’s esophagus), too late (e.g., in a patient’s intestine), or not at all.
  • “gastric residence system” is a dosage form comprising a therapeutic agent and is configured to be administered to a patient in a folded configuration.
  • A“gastric residence dosage form” or“enrobed gastric residence dosage form” comprises a folded gastric residence system and is configured to hold the gastric residence system in a folded configuration until deployment.
  • a gastric residence dosage form may comprise a capsule and/or a capsule coating according to embodiments described herein.
  • a capsule may include a sleeve or band configured to hold the gastric residence system in a folded configuration
  • a gastric residence system folded and retained in a folded configuration with a sleeve or band may be encapsulated by a capsule.
  • an encapsulated gastric residence system may be coated with a capsule coating formulated to control the release of the gastric residence system.
  • an encapsulated gastric residence system may be coated with a reverse-enteric coating.
  • a reverse-enteric coating can encourage dissolution of the capsule in a patient’s stomach, ensuring that the capsule and capsule coating dissolve within the stomach such that the gastric residence system may be released to assume an open configuration.
  • the reverse- enteric coating can also discourage dissolution of the capsule in a patient’s esophagus and/or intestines, preventing premature and/or late release of the gastric residence system.
  • the coating may include a polymer.
  • the coating may include a plasticizer.
  • the coating may include an anti -tacking agent.
  • the coating may include a hydration agent.
  • gastric residence systems and how they operate to deliver a therapeutic agent to a patient.
  • the discussion includes a general description of how gastric residence systems are designed to deliver a therapeutic agent to a patient over an extended period of time, how gastric residence systems are configured for administration, how gastric residence systems are configured to deploy and deliver a therapeutic agent to the stomach of a patient, how the therapeutic agent of a gastric residence system elutes from the device such that the therapeutic agent is delivered to the patient, how the gastric residence system passes through tire stomach, and how gastric residence systems are designed to account for some specific safety measures.
  • Gastric residence dosage forms can be designed to be administered to the stomach of a patient by swallowing, by feeding tube, by gastric tube, etc. Once a gastric residence dosage form is in place in the stomach, it can remain in the stomach for a desired residence time (e.g , three days, seven days, two weeks, etc/). A gastric residence dosage form that is properly in place in a stomach will resist passage through the pyloric valve, which separates the stomach from the small intestine. Gastric residence dosage forms can release a therapeutic agent (i.e., API or drug) over the period of residence with controlled release. While residing in the stomach, the dosage form may not interfere with the normal passage of food or other gastric contents.
  • a therapeutic agent i.e., API or drug
  • the foldable or compactable gastric residence systems shown in Figures 1A-1C are provided in an unfolded configuration.
  • the ring-shaped design gastric residence system 100 shown in Figure 1A can be twisted into a double helix.
  • gastric residence system 100 includes carrier polymer-agent components 102 and couplings 104.
  • coupling 104 may comprise coupling polymer.
  • gastric residence system 100 can be folded at one or more coupling polymer joints 104, or twisted into a helix for packaging into a capsule in its folded configuration.
  • gastric residence system 100 unfolds to the circular shape of its open, or unfolded, configuration, preventing passage through the pyloric valve.
  • gastric residence system 100 may also be star-shaped (stellate) according to some embodiments.
  • a star-shaped gastric residence system 100 is constructed around central elastomer 106.
  • Central elastomer 106 may include one or more elongate member 108, or“arms,” projecting radially.
  • the arms may be formed by carrier polymer-agent components 102 and couplings 104 comprising coupling polymer.
  • the Figure also shows how the carrier polymer-agent components 102 and couplings 104 of each arm may be oriented in a folded configuration.
  • the folded configuration of gastric residence system 100 can be bound (i.e., held in a folded configuration) with a sleeve or band.
  • a gastric residence system in a folded configuration may be encapsulated with a capsule to form a gastric residence dosage form.
  • the gastric residence dosage form may be coated with a reverse-enteric coating to ensure deployment of the gastric residence system in a patient’s stomach.
  • the capsule and/or capsule coating of the gastric residence dosage form may dissolve/open and release the folded gastric residence system.
  • the gastric residence system Upon release, the gastric residence system unfolds to assume an open configuration, such as a ring shape or a star shape as provided in Figures 1A-1C.
  • the dimensions of the open gastric residence system are suitable to prevent passage of the device through the pyloric valve for the period of time during which the device is to reside in the stomach.
  • the folded gastric residence system can also be secured by a dissolvable retaining band or sleeve that can prevent premature deployment of the gastric residence system in case of a failure of the capsule.
  • the gastric residence system While in the stomach, the gastric residence system is compatible with digestion and other normal functioning of the stomach or gastrointestinal tract. The gastric residence system does not interfere with or impede the passage of chyme (partially digested food) or other gastric contents which exit the stomach through the pyloric valve into the duodenum. [0148] Once released from the capsule into the stomach, the therapeutic agent of the gastric residence system begins to take effect.
  • the gastric residence system comprises a plurality of carrier polymer-agent components. The carrier polymer-agent thereof). The plurality of carrier polymer-agent components are linked together by one or more coupling polymer components.
  • a gastric residence system may include a filament (or “webbing”) between arms of a gastric residence system.
  • Gastric residence systems having a filament may help improve the gastric residence of the gastric residence system.
  • a filament can help provide a more consistent gastric residence time and/or a longer gastric residence time.
  • gastric residence systems that include a filament may provide more predictable and/or controllable gastric residence times. Gastric residence systems having predictable and/or controllable gastric residence times can minimize the possibility of the gastric residence system passing through the stomach and unfolding later in the
  • a filament wrapped circumferentially around a gastric residence system and connecting the arms of the gastric residence system can help prevent premature passage through a patient’s gastric pylorus.
  • coatings can be applied to outer surfaces of the gastric residence system. The coatings can include additional therapeutic agents or agents that can affect the release of therapeutic agents or the residence duration of the gastric residence system.
  • various components of the gastric delivery system are designed to weaken and degrade.
  • the specific dimensions of the system are also taken into consideration.
  • the gastric residence system In its intact, open configuration, the gastric residence system is designed to resist passage through the pyloric valve.
  • coupling polymer components of the gastric residence system are chosen such that they gradually degrade over the specified residence period in the stomach.
  • the reduced-size dosage form and any smaller pieces are designed to pass through the pyloric valve. The system then passes through the intestines and is eliminated from the patient.
  • a gastric residence system may be made of soft material such that the gastric residence system can pass through a pyloric valve intact once the residence time expires without degrading into numerous smaller pieces.
  • Examples of gastric residence systems may be found in PCT/US2018/051816, WO 2015/191920, WO 2017/070612, WO 2017/100367, WO 2018/064630, WO 2017/205844, WO 2018/227147, and US 62/933,211, each of which is incorporated herein in its entirety.
  • CAPSULES FOR GASTRIC RESIDENCE SYSTEMS [0155] Following is a description of capsules for gastric residence systems, including both sleeves (or bands) and capsules (e.g., hard-shell capsules). In particular, sleeves/bands as described below may be used to hold a gastric residence system in a folded configuration.
  • Capsules may be used to encapsulate the gastric residence system (with or without a sleeve) and control when the gastric residence system is released in a patient’s stomach.
  • Capsules have been developed according to embodiments provided herein to enhance gastric residence system performance. Specifically, capsules have been developed to retain a gastric residence system in a folded configuration between the time of administration and the time it reaches the stomach. Once the gastric residence dosage form reaches the stomach, the capsule is configured to open and/or dissolve rapidly. A rapidly-opening or rapidly-dissolving capsule can ensure that the gastric residence system is released within the stomach before passing through the pyloric valve.
  • Figure 3B shows compacted/folded gastric residence system 310 bound by sleeve 312 according to some embodiments. As shown, gastric residence system 310, in its folded configuration, is capped off at the arm end by sleeve 312. [0159] Figure 4B shows a compacted/folded gastric residence system 410 bound by sleeve 412 according to some embodiments. Unlike sleeve 312 of Figure 3B, sleeve 412 of Figure 4B includes two open ends.
  • suitable sleeves can include VCaps® HPMC, VCaps® Plus HPMC, Plantcaps®, or ConiSnap®.
  • the sleeve size and/or thickness may be optimized to control deployment time of a gastric residence system. For example, a sleeve having a thinner shell thickness may be used to release the gastric residence system faster. In some embodiments, a sleeve having a thicker shell thickness may be used to release the gastric residence system slower. In some embodiments, a sleeve having a smaller length and/or width may be used to control the release of a gastric residence system from the gastric residence dosage form.
  • a sleeve having a larger length and/or width may be used to control the release of a gastric residence system from the gastric residence dosage form.
  • a sleeve having a larger length/width may help delay the release of a gastric residence system.
  • a sleeve having a shorter length/width may be used to speed the release of a gastric residence system.
  • the placement of the sleeve on a folded gastric residence system may also be optimized to control deployment time.
  • the position of the sleeve may be optimized with respect to the folding force and/or with respect to the positioning of the body and/or cap of the capsule.
  • some embodiments may include a wicking material between the sleeve and a folded gastric residence system.
  • a wicking material may help a gastric residence system deploy faster.
  • the wicking material may comprise a hydrophilic polymer, a hygroscopic polymer, a hygroscopic wetting agent, and/or a humectant.
  • Polymeric examples may include polysaccharide-based polymers such as hydroxypropyl methylcellulose, carboxymethylcellulose, starch, pectin, chitosan, alginate, other natural or semi-synthetic polymers like gelatin collagen, silk fibroin, and/or non- cellulosic synthetic polymers like polyethylene glycol, polyethyl glycol-polypropylene glycol di- and tri-block copolymers, polyvinylpyrrolidone, and derivatives thereof.
  • polysaccharide-based polymers such as hydroxypropyl methylcellulose, carboxymethylcellulose, starch, pectin, chitosan, alginate, other natural or semi-synthetic polymers like gelatin collagen, silk fibroin, and/or non- cellulosic synthetic polymers like polyethylene glycol, polyethyl glycol-polypropylene glycol di- and tri-block copolymers, polyvinylpyrrolidone, and derivatives thereof
  • Capsules can offer various advantages that include protection, blinding capabilities, and good coating adherence.
  • a capsule provides resistance to physical impact and external environmental factors (e.g., humidity). This layer of protection can improve the shelf-life of the gastric resident dosage form and protect it during transport
  • capsules are opaque to allow for blinding (i.e., for use in clinical studies).
  • the capsules offer a suitable surface for capsule coatings (described in detail below). Capsule coatings according to embodiments provided herein suitably adhere to the surface of capsules.
  • capsules and/or sleeves according to embodiments provided herein are designed to protect a patient against esophageal deployment.
  • the deployment time of a capsule and/or sleeve in a pH 7.0 environment may be from 5 to 180 minutes, from 20 to 120 minutes, or from 20 to 60 minutes.
  • the deployment time of a capsule and/or sleeve in an aqueous pH 7.0 environment may be less than 180 minutes, less than 160 minutes, less than 140 minutes, less than 120 minutes, less than 100 minutes, less than 80 minutes, less than 60 minutes, less than 50 minutes, less than 40 minutes, less than 30 minutes, less than 25 minutes, or less than 20 minutes.
  • capsules and/or sleeves according to embodiments provided herein are designed to dissolve/open rapidly and consistently. In some embodiments, the dissolution/opening of the capsule and/or sleeve has little or no reliance on a low pH. [0167] Additionally, encapsulating gastric residence systems with capsules according to embodiments provided herein allows for a slippery, non-adhesive surface for ease of swallowing (to prevent esophageal holdups) and a non-tacky and defect-free processing, storage, and shipment phases.
  • the capsules may be gelatin-based.
  • the capsules and/or sleeves may be hydroxypropyl methylcellulose (HPMC)-based or pullulan- based.
  • HPMC hydroxypropyl methylcellulose
  • suitable materials e.g., carrageenan, starch, cellulose, etc.
  • suitable capsules can include VCaps® HPMC, VCaps® Plus HPMC, Plantcaps®, or Coni-Snap®.
  • the capsule size and/or thickness may be optimized to control deployment time of a gastric residence system.
  • a capsule having a thinner shell thickness may be used to release the gastric residence system faster.
  • a capsule having a thicker shell thickness may be used to release the gastric residence system slower.
  • a capsule having a smaller length and/or width may be used to control the release of a gastric residence system from the gastric residence dosage form.
  • a capsule having a larger length and/or width may be used to control the release of a gastric residence system from the gastric residence dosage form.
  • a capsule having a larger length/width may help delay the release of a gastric residence system.
  • a capsule having a shorter length/width may be used to speed the release of a gastric residence system.
  • a folded gastric residence system (bound with a sleeve or unbound) may be inserted into a two-piece capsule using any suitable encapsulation technique.
  • a gastric residence system may be manually folded and encapsulated.
  • the sleeve may be a size 0 or 0EL capsule cap.
  • the gastric residence system may be encapsulated with the sleeved end of the gastric residence system in the body of the two-piece capsule.
  • FIG. 3A-3D and Figure 4A-4D show the steps of encapsulation according to some embodiments.
  • Sleeve 312 of Figures 3A-3D is a full cap that fits on one end of folded gastric residence system 310.
  • Sleeve 412 of Figures 4A-4D has a cylindrical shape with an open top and an open bottom.
  • Figure 4D shows the body 414 including the sleeved gastric residence system 410 being capped off with cap 416 of the two-piece capsule.
  • the configuration of the sleeve and/or the two-piece capsule can vary depending on the gastric residence dosage form. In some embodiments, the placement of the sleeve and/or the two-piece capsule relative to the core side and the arm side of the gastric residence system may have an impact on the deployment time of the gastric residence system.
  • Figures 5A-5C show a few different configurations for sleeve and two-piece capsule placement. Specifically, Figure 5A shows a compacted/folded gastric residence system 510A.
  • gastric residence system 510A can be sleeved by capsule sleeve 512A.
  • Figure 5A shows gastric residence system 510A sleeved on the core side of the folded gastric residence system 510A.
  • gastric residence system 510A may be sleeved on an arm side in some embodiments.
  • the core side of gastric residence system 510A is shaded.
  • the opposing side of compacted/folded gastric residence system 510A is the arm side, where the arms converge when the gastric residence system is folded.
  • FIG. 5B shows a sleeved compacted/folded gastric residence system 540B being encapsulated with a two-piece capsule.
  • sleeved compacted/folded gastric residence system 540B is sleeved on the core side of the gastric residence system, like that of sleeved compacted/folded gastric residence system 540A of Figure 5A.
  • Cap 516B of the two- piece capsule is placed over the sleeve of sleeved compacted/folded gastric residence system 540B (i.e., on the core side of the gastric residence system).
  • Body 514B of the two-piece capsule is placed over the arm side of the compacted/folded gastric residence system.
  • encapsulated gastric residence dosage form 542 is formed. Additionally, cap 516B and body 514B may overlap to an extent to form a seal protecting encapsulated gastric residence dosage form 542B from the exterior environment.
  • Figure 5C also shows a sleeved compacted/folded gastric residence system 540C encapsulated with a two-piece capsule.
  • sleeved compacted/folded gastric residence system 540C is encapsulated with a two-piece capsule such that the body of the two-piece capsule, body 514C, encases the sleeve of sleeved compacted/folded gastric residence system 540C.
  • the cap of the two-piece capsule, cap 516C is placed over the arm side of the
  • Cap 516C and body 514C may overlap to an extent to form a seal protecting encapsulated gastric residence dosage form 542B from the exterior environment.
  • CAPSULE COATINGS FOR GASTRIC RESIDENCE DOSAGE FORMS [0177] Following is a description of capsule coatings for gastric residence systems. In particular, capsule coatings described below may be used to delay capsule
  • capsule coatings described below may speed up capsule opening when the gastric residence dosage form is in the stomach. As described below, capsule coatings may provide a protective moisture barrier, encourage gastric dissolution, encourage passage through the esophagus, and provide a more pleasant administration experience for the patient. [0178] In some embodiments, capsules described herein may be coated with a reverse-enteric low-friction static coefficient polymer. A reverse-enteric low-friction static coefficient polymer coating may help encourage passage of the coated capsule through the esophagus, minimizing the risk of pill esophagitis.
  • the presence of a reverse-enteric polymer and/or magnesium stearate in the coating may lower the static coefficient of friction of the dosage form.
  • Some specific drugs/APIs in particular have a tendency to cause esophagitis such as doxycycline, tetracycline, clindamycin, other antibiotics, potassium chloride, bisphosphonates, and non-steroidal anti-inflammatory drugs.
  • Some of these APIs can pose a health risk if they cause esophagitis. Thus, ensuring that they pass easily through the esophagus can help prevent esophagitis.
  • the reverse-enteric low-friction static coefficient polymer coating may be applied to the exterior surface of a dosage form.
  • 0.8 less than 0.7, less than 0.6, less than 0.5, less than 0.4, or less than 0.3. In some embodiments, may be more than 0.2, more
  • the static coefficient of friction of a coated dosage form may be from 5-80%, from 20-80%, or from 50-80% that of an uncoated dosage form. In some embodiments, the static coefficient of friction of a coated dosage form may be less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, or less than 10% that of an uncoated dosage form. In some embodiments, the static coefficient of friction of a coated dosage form may be more than 5%, more than 10%, more than 20%, more than 30%, more than 40%, more than 50%, more than 60%, or more than 70% that of an uncoated dosage form.
  • the static coefficient of friction of a coated dosage form may be from 0.05 to 0.35, or from 0.1 to 0.2 less than that of an uncoated dosage form. In some embodiments, the static coefficient of friction of a coated dosage form may be less than 0.35, less than 0.3, less than 0.25, less than 0.2, less than 0.15, or less than 0.1, or coefficient of friction of a coated dosage form maybe more than 0.05, more than 0.08, more than 0.1, more than 0.15, more than 0.2, more than 0.25, or more than 0.3 less than that of an uncoated dosage form.
  • the first amount of time may be more than 15 seconds, more than 30 seconds, more than 45 seconds, more than 1 minute, more than 3 minutes, more than 5 minutes, more than 8 minutes, more than 10 minutes, more than 12 minutes, or more than 15 minutes greater than the second amount of time. In some embodiments, the first amount of time may be less than 20 minutes, less than 18 minutes, less than 15 minutes, less than 12 minutes, less than 10 minutes, less than 8 minutes, less than 5 minutes, less than 3 minutes, less than 1 minute, less than 45 seconds, or less than 30 seconds greater than the second amount of time.
  • the third amount of time may be more than 15 seconds, more than 30 seconds, more than 45 seconds, more than 1 minute, more than 3 minutes, more than 5 minutes, more than 8 minutes, more than 10 minutes, more than 12 minutes, or more than 15 minutes greater than the fourth amount of time. In some embodiments, the third amount of time may be less than 20 minutes, less than 18 minutes, less than 15 minutes, less than 12 minutes, less than 10 minutes, less than 8 minutes, less than 5 minutes, less than 3 minutes, less than 1 minute, less than 45 seconds, or less than 30 seconds greater than the fourth amount of time.
  • a coated gastric residence dosage form may release a gastric residence system and allow it to assume an open configuration after residing in an aqueous pH 7.0 environment for less than 120 minutes, less than 100 minutes, less than 80 minutes, less than 60 minutes, less than 50 minutes, less than 40 minutes, or less than 30 minutes.
  • a coated gastric residence dosage form may release a gastric residence system and allow it to assume an open configuration after residing in an aqueous pH 7.0 environment for more than 20 minutes, more than 30 minutes, more than 40 minutes, more than 50 minutes, more than 60 minutes, more than 80 minutes, or more than 100 minutes.
  • a coated gastric residence dosage form may release a gastric residence system and allow it to assume an open configuration after residing in an aqueous pH 3.0 environment from 10 seconds to 30 minutes, from 30 seconds to 20 minutes, or from 1 minute to 10 minutes.
  • a coated gastric residence dosage form may release a gastric residence system and allow it to assume an open configuration after residing in an aqueous pH 3.0 environment for more than 10 seconds, more than 20 seconds, more than 30 seconds, more than 40 seconds, more than 50 seconds, more than 1 minute, more than 2 minutes, more than 3 minutes, more than 4 minutes, more than 5 minutes, more than 10 minutes, more than 15 minutes, more than 20 minutes, or more than 25 minutes.
  • a coated gastric residence dosage form may release a gastric residence system and allow it to assume an open configuration after residing in an aqueous pH 3.0 environment for less than 30 minutes, less than 25 minutes, less than 20 minutes, less than 15 minutes, less than 10 minutes, less than 5 minutes, less than 4 minutes, less than 3 minutes, less than 2 minutes, less than 1 minute, less than 50 seconds, less than 40 seconds, less than 30 seconds, or less than 20 seconds.
  • Capsule coatings according to embodiments provided herein may include a polymer, a plasticizer, an anti-tacking agent, and/or a hydration aid.
  • the polymer may be a reverse-enteric polymer.
  • a reverse- enteric polymer can encourage dissolution of the capsule in a gastric environment (e.g., pH 1.5-3.0).
  • a reverse-enteric polymer can also provide a moisture barrier to the capsule.
  • a suitable reverse-enteric polymer may have desirable physiochemical dissolution properties, have good film-forming capacity, and be suitable for pharmaceutical coating methods (e.g., pan-coating).
  • polymethacrylates are suitable reverse-enteric polymers.
  • polymers include a diverse range of polymethacrylate-based copolymers specifically formulated to aid in targeted drug release.
  • Eudragit® E may be a suitable reverse-enteric polymer.
  • the coating formulation may include small molecule additives with enhanced solubility at reduced pH (e.g., tertiary amine, imidazole-containing chemical entities, etc.).
  • a dry capsule coating composition on a capsule may include from 40 to 95 wt. %, from 50 to 80 wt. %, or from 60 to 70 wt. % polymer to total solids.
  • a dry capsule coating composition on a capsule may include less than 95 wt. %, less than 90 wt. %, less than 85 wt. %, less than 80 wt. %, less than 75 wt. %, less than 70 wt. %, less than 65 wt.
  • a liquid capsule coating composition may include less than 30 wt. %, less than 28 wt. %, less than 25 wt. %, less than 23 wt. %, less than 20 wt. %, less than 18 wt. %, less than 15 wt. %, less than 12 wt. %, less than 10 wt. %, less than 8 wt. %, or less than 5 wt. % polymer.
  • Plasticizers in the coating formulation may reduce brittleness by enhancing the flexibility, resilience, and adhesion of the coating to the underlying capsule surface.
  • Suitable plasticizers may include phthalates, phosphates, citrates, tartrates, adipates, sebacates, sulfonamides, succinates, glycolates, glycerolates, benzoates, myristates, halogenated phenyls, and poloxamers.
  • Specific compounds that may be used as a plasticizer in the coating formulation can include triacetin, triethyl citrate, polyethylene glycol, and dibutyl sebacate.
  • a dry capsule coating composition on a capsule may include from 1 to 30 wt. %, from 1 to 20 wt. %, or from 1 to 10 wt. % plasticizer to total solids.
  • a liquid capsule coating composition may include more than 0.1 wt. %, more than 0.2 wt. %, more than 0.3 wt. %, more than 0.4 wt. %, more than 0.5 wt. %, more than 0.6 wt. %, more than 0.7 wt. %, more than 0.8 wt. %, more than 0.9 wt. %, more than 1.0 wt. %, more than 1.5 wt. %, more than 2.0 wt. %, more than 2.5 wt. %, more than 3.0 wt. %, or more than 4.0 wt.
  • a liquid capsule coating composition may include less than 5.0 wt. %, less than 4.0 wt. %, less than 3.5 wt. %, less than 3.0 wt.%, less than 2.5 wt. %, less than 2.0 wt. %, 1.5 wt. %, less than 1.0 wt. %, less than 0.9 wt. %, less than 0.8 wt. %, less than 0.7 wt. %, less than 0.6 wt. %, less than 0.5 wt. %, less than 0.4 wt. %, less than 0.3 wt.%, or less than 0.2 wt. % plasticizer.
  • An anti-tacking agent in the capsule coating formulation may help prevent capsule tackiness during process and storage. Additionally, certain anti-tacking agents may improve the lubricity of the coated capsules and provide a glossy and smooth surface finish. Suitable anti-tacking agents may include bulk-acting agents (e.g., talc) and surface-acting agents (e.g., magnesium stearate). In some embodiments, magnesium stearate in particular may help decrease the static coefficient of friction of a coated encapsulated gastric residence system. In some embodiments, a coating comprising magnesium stearate may be able to lower the static coefficient of friction to less than 0.1, or such that
  • a dry capsule coating composition on a capsule may include from 1 to 40 wt. %, from 1 to 25 wt. %, or from 1 to 10 wt. % anti-tacking agent to total solids. In some embodiments, a dry capsule coating composition on a capsule may include less than 40 wt. %, less than 35 wt. %, less than 30 wt. %, less than 25 wt. %, less than 20 wt. %, less than 15 wt. %, less than 10 wt.
  • a dry capsule coating composition on a capsule may include more than 1 wt. %, more than 2 wt. %, more than 3 wt. %, more than 4 wt. %, more than 5 wt. %, more than 6 wt. %, more than 7 wt. %, more than 8 wt. %.
  • a liquid capsule coating composition (i.e., in solution, prior to drying on the surface of a capsule) may include from 0.1 to 5.0 wt. %, from 0.2 to 3.0 wt. %, or from 0.3 to 1.0 wt. % anti-tacking agent. In some embodiments, a liquid capsule coating composition may include more than 0.1 wt.
  • a liquid capsule coating composition may include less than 5.0 wt.
  • wt. % less than 4.0 wt. %, less than 3.5 wt. %, less than 3.0 wt.%, less than 2.5 wt. %, less than 2.0 wt. %, 1.5 wt. %, less than 1.0 wt. %, less than 0.9 wt. %, less than 0.8 wt. %, less than 0.7 wt. %, less than 0.6 wt. %, less than 0.5 wt. %, less than 0.4 wt. %, less than 0.3 wt.%, or less than 0.2 wt. % anti-tacking agent.
  • a dry capsule coating composition on a capsule may include more than 2 wt. %, more than 5 wt. %, more than 10 wt. %, more than 15 wt. %, more than 20 wt. %, more than 25 wt. %, more than 30 wt.
  • a liquid capsule coating composition (i.e., in solution, prior to drying on the surface of a capsule) may include from 0.1 to 5.0 wt. %, from 0.2 to 3.0 wt. %, or from 0.3 to 1.0 wt. % hydration aid.
  • a liquid capsule coating composition may include more than 0.1 wt. %, more than 0.2 wt. %, more than 0.3 wt. %, more than 0.4 wt. %, more than 0.5 wt.
  • a liquid capsule coating composition may include less than 5.0 wt. %, less than 4.0 wt. %, less than 3.5 wt. %, less than 3.0 wt.%, less than 2.5 wt. %, less than 2.0 wt.
  • Capsule coating compositions according to embodiments provided herein may be soluble in a variety of solvents.
  • capsule coating compositions may be soluble in aqueous solvents and/or organic solvents.
  • a liquid coating composition in solution may include from 55 to 97 wt. % solvent.
  • a liquid coating composition in solution may include more than 55 wt. %, more than 60 wt. %, more than 65 wt. %, more than 70 wt. %, more than 75 wt. %, more than 80 wt. %, more than 85 wt. %, more than 90 wt. %, or more than 95 wt. % solvent.
  • a liquid coating composition in solution may include less than 97 wt. %, less than 95 wt.
  • Capsule coating compositions according to embodiments provided herein may include additional components other than those already described above.
  • a pH- modifying buffer may be used to help accelerate dissolution of the coating in a mild acid (i.e., in a gastric environment).
  • pH-modifying buffers may include an imidazole- based buffer or an imidazole- or histatide-titrated with carboxylic acid buffer system.
  • a sleeve coating composition may comprise a hydrophilic and/or hygroscopic polymer or alternatively a hygroscopic wetting agent or humectant.
  • Polymeric examples may include polysaccharide- based polymers such as hydroxypropyl methylcellulose, carboxymethylcellulose, starch, pectin, chitosan, alginate, other natural or semi-synthetic polymers like gelatin collagen, silk fibroin and/or non-cellulosic synthetic polymers like polyethylene glycol, polyethyl glycol- polypropylene glycol di- and tri-block copolymers, polyvinylpyrrolidone, and derivatives thereof.
  • Figure 6D shows the two-piece capsule (comprising body 614 and cap 616) coated with capsule coating 620.
  • ENROBING ENCAPSULATED GASTRIC RESIDENCE SYSTEMS [0200] Following is a description of coating compositions for enrobing folded gastric residence systems.
  • a coating composition may include a polymer, a plasticizer, a gelling agent and/or a solvent.
  • the term“coating” may refer to“enrobing.”“Enrobing” includes surrounding a folded gastric residence system with a softgel type shell material to form an “enrobed gastric residence system.”“Coating” may also refer to a coating applied to the exterior of an enrobed gastric residence device.
  • a coating for enrobing a folded gastric residence system can protect the therapeutic agent (and in this case, the gastric residence system) from tampering. Additionally, enrobed gastric residence dosage forms can be easier to swallow than gastric residence systems encapsulated only in conventional capsules, which can help reduce the transit time in the esophagus and minimize any chance of the gastric residence system releasing and unfolding in the esophagus.
  • enrobing gastric residence systems with a coating composition according to embodiments provided herein allows for a slippery, non-adhesive surface for ease of swallowing (to prevent esophageal holdups) and a non-tacky and defect-free processing storage and shipment phases
  • coating compositions according to embodiments provided herein are designed to protect a patient against esophageal deployment.
  • the deployment time of an enrobed gastric residence dosage form in an aqueous pH 7.0 environment i.e., the approximate pH of the esophagus
  • a gastric residence dosage form As described above, once a gastric residence dosage form has reached the stomach, it should dissolve rapidly to allow the gastric residence system to deploy in the stomach. If the coating material fails to dissolve rapidly, then the gastric residence dosage form risks passing through the pyloric valve prior to releasing the gastric residence system. Accordingly, coating compositions according to embodiments provided herein are designed to dissolve rapidly and consistently. In some embodiments, the dissolution of the coating material has little or no reliance on a low pH. [0207] For example, an enrobed gastric residence dosage form may deploy after residing in an aqueous pH 3.0 environment from 1 to 60 minutes, from 5 to 45 minutes, or from 10 to 30 minutes.
  • an enrobed gastric residence dosage form may deploy after residing in an aqueous pH 3.0 environment for more than 1 minutes, more than 2 minutes, more than 3 minutes, more than 4 minutes, more than 5 minutes, more than 10 minutes, more than 15 minutes, more than 20 minutes, more than 25 minutes, more than 30 minutes, more than 35 minutes, more than 40 minutes, more than 45 minutes, more than 50 minutes, or more than 55 minutes.
  • an enrobed gastric residence dosage form may deploy in an aqueous pH 3.0 environment for less than 60 minutes, less than 55 minutes, less than 50 minutes, less than 45 minutes, less than 40 minutes, less than 35 minutes, less than 30 minutes, less than 25 minutes, less than 20 minutes, less than 15 minutes, less than 10 minutes, less than 5 minutes, less than 4 minutes, less than 3 minutes, or less than 2 minutes.
  • the thickness of the coating for enrobing gastric residence devices in folded configurations may vary depending on desired properties of the enrobed gastric residence dosage form (e.g., deployment time). In some embodiments, the thickness of the coating enrobing the folded gastric residence system may be from 50 to 700 microns or from 150 to 350 microns thick.
  • the thickness of the coating enrobing the folded gastric residence system may be more than 50 microns, more than 100 microns, more than 150 microns, more than 200 microns, more than 250 microns, more than 300 microns, more than 350 microns, more than 400 microns, more than 450 microns, more than 500 microns, more than 550 microns, more than 600 microns, or more than 650 microns thick.
  • the thickness of the coating enrobing the folded gastric residence system may be less than 700 microns, less than 650 microns, less than 600 microns, less than 550 microns, less than 500 microns, less than 450 microns, less than 400 microns, less than 350 microns, less than 300 microns, less than 250 microns, less than 200 microns, less than 150 microns, or less than 100 microns thick.
  • the coating for enrobing folded gastric residence systems may provide a hermetic seal.
  • the coating may hermetically seal the folded gastric residence system to form an enrobed gastric residence dosage form.
  • the coating formulation may include small molecule additives with enhanced solubility at reduced pH (e.g., tertiary amine, imidazole-containing chemical entities, etc.).
  • the coating composition may include from 10 to 70 wt. %, from 20 to 60 wt. %, or from 30 to 50 wt. % polymer.
  • the coating composition may include less than 70 wt. %, less than 65 wt. %, less than 60 wt. %, less than 55 wt. %, less than 50 wt. %, less than 45 wt. %, less than 40 wt. %, less than 35 wt. %, less than 30 wt. %, less than 25 wt. %, less than 20 wt. %, or less than 15 wt. % polymer. In some embodiments, the coating composition may include more than 10 wt. %, more than 15 wt. %, more than 20 wt. %, more than 25 wt. %, more than 30 wt.
  • Plasticizers in the coating composition may reduce brittleness by enhancing the flexibility and resilience of the enrobed gastric residence dosage form.
  • the coating composition may include less than 70 wt. %, less than 65 wt. %, less than 60 wt. %, less than 55 wt. %, less than 50 wt. %, less than 45 wt. %, less than 40 wt. %, less than 35 wt. %, less than 30 wt. %, less than 25 wt. %, less than 20 wt. %, or less than 15 wt. % plasticizer.
  • the coating composition may include more than 10 wt. %, more than 15 wt. %, more than 20 wt. %, more than 25 wt. %, more than 30 wt.
  • Coating compositions according to embodiments provided herein include a gelling agent.
  • suitable gelling agents may include gelatin, pullulan, hydroxypropyl methylcellulose, and/or potato starch.
  • the bloom strength of the gelatin may be from 100 to 300 or from 150 to 250. In some embodiments, the bloom strength of the gelatin may be more than 100, more than 150, more than 200, or more than 250. In some embodiments, the bloom strength of the gelatin may be less than 300, less than 250, less than 200, or less than 150. [0213] In some embodiments, the coating composition may include from 30 to 80 wt. %, from 40 to 70 wt. %, or from 50 to 60 wt. % gelling agent. In some embodiments, the coating composition may include less than 80 wt. %, less than 75 wt. %, less than 70 wt. %, less than 65 wt.
  • the coating composition may include more than 30 wt. %, more than 35 wt. %, more than 40 wt. %, more than 45 wt. %, more than 50 wt. %, more than 55 wt. %, more than 60 wt. %, more than 65 wt. %, more than 70 wt. %, or more than 75 wt. % gelling agent.
  • Coating compositions according to embodiments provided herein may include additional components other than those already described above.
  • opacifiers, colorants, flavors, and/or preservatives may also be used in coating compositions described herein.
  • a suitable opacifier may include titanium dioxide.
  • Suitable colorants may include FDA-approved dyes and lakes.
  • Suitable flavors include ethyl vanillin and sucrose.
  • Suitable preservatives include parabens, such as methyl paraben or propyl paraben.
  • ENCAPSULATION AND COATING PROCESS [0216] Gastric residence systems may be encapsulated and/or coated using any suitable encapsulation and/or coating technique.
  • FIG. 7 provides a schematic showing a method 600 of preparing a gastric residence dosage form according to some embodiments.
  • a folded gastric residence system is encapsulated in a capsule.
  • step 702 of the method may include folding the gastric residence system and inserting the folded gastric residence system into a container. Step 702 may be performed either manually or mechanically.
  • Folding the gastric residence system may include compacting or compressing the gastric residence system into its folded configuration. Inserting the gastric residence system into a container may include inserting the compacted gastric residence system into a capsule or other container of appropriate size.
  • methods for preparing a gastric residence dosage form may include receiving the foldable gastric residence system in an unfolded form. For example, the foldable gastric residence system can be received at a vibratory bowl feeder or a pick and place conveyor.
  • methods for preparing a gastric residence dosage form may include orienting the gastric residence system into a folding position. Methods may also include folding the gastric residence system into a folded configuration.
  • an encapsulated gastric residence system may be coated with a reverse-enteric coating.
  • a pan-coating process may be used to coat the encapsulated gastric residence systems.
  • an LDCS 48098/Freund-Vector pan coater may be used with a 1.5L pan size, a SCHLICK ABC LDCS-FP HCC-6869-3 spray gun, and peroxide-cured silicone pump tubing to coat the encapsulated gastric residence systems.
  • empty capsules may be coated before they are used to encapsulate gastric residence systems.
  • the coater airflow may be more than 20 CFM, more than 30 CFM, more than 40 CFM, more than 50 CFM, or more than 60 CFM.
  • the pan speed may be from 10 to 50 rpm, from 15 to 40 rpm, or from 20 to 30 rpm. In some embodiments, the pan speed may be more than 10 rpm, more than 15 rpm, more than 20 rpm, more than 30 rpm, or more than 40 rpm. In some embodiments, the pan speed may be less than 50 rpm, less than 40 rpm, less than 30 rpm, less than 20 rpm, or less than 15 rpm.
  • the pump speed may be from 2 to 15 rpm, from 3 to 12 rpm, or from 5 to 10 rpm. In some embodiments, the pump speed may be more than 2 rpm, more than 3 rpm, more than 5 rpm, or more than 10 rpm. In some embodiments, the pump speed may be less than 15 rpm, less than 12 rpm, less than 10 rpm, or less than 5 rpm.
  • the atomization pressure may be from 10 to 40 pounds per square inch (psi), from 15 to 35 psi, or from 20 to 30 psi.
  • the atomization pressure may be more than 10 psi, more than 15 psi, more than 20 psi, or more than 25 psi. In some embodiments, the atomization pressure may be less than 40 psi, less than 35 psi, less than 30 psi, less than 25 psi, or less than 20 psi. [0227] The pattern pressure may be from 10 to 40 psi, from 15 to 35 psi, or from 20 to 30 psi. In some embodiments, the pattern pressure may be more than 10 psi, more than 15 psi, more than 20 psi, or more than 25 psi.
  • the pattern pressure may be less than 40 psi, less than 35 psi, less than 30 psi, less than 25 psi, or less than 20 psi.
  • the spray rate may be from 1 to 10 grams per minute (g/min) or from 3 to 8 g/min. In some embodiments, the spray rate may be more than 1 g/min, more than 2 g/min, more than 3 g/min, more than 4 g/min, or more than 5 g/min. In some embodiments, the spray rate may be less than 10 g/min, less than 8 g/min, less than 6 g/min, less than 5 g/min, or less than 4 g/min.
  • the drying pan speed may be from 1 to 30 rpm, from 3 to 20 rpm, or from 5 to 10 rpm. In some embodiments, the drying pan speed may be more than 1 rpm, more than 2 rpm, more than 3 rpm, more than 4 rpm, more than 5 rpm, more than 8 rpm, more than 10 rpm, or more than 15 rpm. In some embodiments, the drying pan speed may be less than 30 rpm, less than 25 rpm, less than 20 rpm, less than 15 rpm, less than 10 rpm, less than 8 rpm, or less than 5 rpm.
  • the total drying time in pan may be from 15 to 120 minutes, from 30 to 100 minutes, or from 45 to 80 minutes. In some embodiments, the total drying time in pan may be more than 15 minutes, more than 30 minutes, more than 45 minutes, more than 60 minutes, or more than 80 minutes. In some embodiments, the total drying time in pan may be less than 120 minutes, less than 100 minutes, less than 80 minutes, less than 60 minutes, or less than 45 minutes. In some embodiments, the drying time may be continuous. In some embodiments, the drying time may be discontinuous. [0231] The capsule coating may comprise from 0.2 to 15 wt. %, from 0.5 to 10 wt. %, or from 1 to 5 wt. % of the total gastric residence dosage form.
  • the capsule coating may comprise more than 0.2 wt. %, more than 0.5 wt. %, more than 0.8 wt. %, more than 1.0 wt. %, more than 1.5 wt. %, more than 2.0 wt. %, more than 2.5 wt. %, more than 3.0 wt. %, more than 3.5 wt. %, more than 4.0 wt. %, or more than 4.5 wt. % of the total gastric residence dosage form.
  • the capsule coating may comprise less than 5.0 wt. %, less than 4.5 wt. %, less than 4.0 wt. %, less than 3.5 wt.
  • Example 1 Provided below are testing data for various capsule coating compositions. Specifically, the data show the effects that different types and amounts of hydration aid can have on dissolution of the capsule in both neutral (i.e., esophageal) and acidic (i.e., gastric) pH environments.
  • the data show tackiness of the capsules on storage, pan- coating processability observations, and static coefficient of friction (i.e., effects on swallowing).
  • the polymer used was Eudragit® E, the anti-tacking agent was magnesium stearate, the plasticizer was triacetin, and the solvent used was isopropyl alcohol. The testing was performed according to the techniques discussed in detail further below.
  • Example 2 Different types of capsules were tested for deployment time. Both unsleeved gastric residence systems and sleeved gastric residence systems were tested. The sleeved gastric residence systems were sleeved on the arm side of the compacted/folded gastric residence system. As shown in Table 2 below, gelatin capsules (Coni-Snap®), HPMC capsules (VCaps® Plus), and pullulan capsules (Plantcaps®) were tested. In addition to deployment time, observations on dissolution were also obtained. The sleeves used were size 0EL VCaps® Plus HPMC. The testing was performed according to the techniques discussed in detail further below.
  • Example 3 The deployment time of gastric residence systems comprising a filament and sleeved on the arm-side of and the deployment time of gastric residence systems comprising a filament and sleeved on the core side was tested.
  • some gastric residence systems such as stellate-shaped gastric residence systems, are configured to compact/fold at the core.
  • the gastric residence system has an arm side and a core side (e.g., as shown in Figures 2, 5A-5C, and 6A).
  • Figures 8A-8G shows different sleeving and encapsulation configurations for gastric residence systems comprising a filament. Specifically, Figure 8A shows a compacted/folded gastric residence system 810A that is being sleeved on an arm side with sleeve 812A.
  • Compacted/folded gastric residence system 810A comprises a filament between each arm of the gastric residence system.
  • the filament of the gastric residence system is covered by sleeve 812A.
  • Figure 8B shows gastric residence system 810A sleeved with sleeve 812A on the arm side of the gastric residence system to form sleeved compacted/folded gastric residence system 840B.
  • Figure 8C shows a compacted/folded gastric residence system 810C. However, compacted/folded gastric residence system 810C is shown being sleeved on the core side of the gastric residence system with sleeve 812C.
  • Figure 8D shows
  • compacted/folded gastric residence system 810D sleeved with sleeve 812C on the core side of the gastric residence system.
  • the webbing of compacted/folded gastric residence system 810C is not covered by sleeve 812C in sleeved compacted/folded gastric residence system 840D.
  • Figures 8E and 8F show different encapsulation configurations for sleeved compacted/folded gastric residence systems.
  • Both sleeved compacted/folded gastric residence system 840E of Figure 8E and sleeved compacted/folded gastric residence system 840F of Figure 8F are sleeved on an arm side of the gastric residence system.
  • Figure 8E shows sleeved gastric residence system 840E being encapsulated with a two-piece capsule.
  • the cap of the two-piece capsule, cap 816E is shown encapsulating the sleeved gastric residence system on its core side
  • the body of the two-piece capsule, body 814E is shown encapsulating the sleeved gastric residence system on its sleeved arm side.
  • Figure 8F shows sleeved gastric residence system 840F being encapsulating with a two-piece capsule.
  • the sleeved compacted/folded gastric residence system 840F of Figure 8F is being encapsulated with the body of the two-piece capsule, body 814F, encapsulating the core side, and the cap of the two-piece capsule, cap 816F encapsulating the sleeved arm side of the gastric residence system.
  • Figure 8G shows an encapsulated sleeved compacted/folded gastric residence system 842G.
  • the sleeve used in these trials were VCaps ® Plus HPMC size 0.
  • Table 3 shows deployment time data for arm-side sleeved gastric residence systems
  • Table 4 shows deployment time data for core-side sleeved gastric residence systems. The data of both Tables 3 and 4 was obtained using the Deployment (Rocker) test at pH 7, described in further detail below.
  • Example 4 The deployment time of gastric residence dosage forms comprising a coated capsule with were tested with both sleeved and unsleeved gastric residence systems to evaluate the effect of the sleeve on deployment time. Based on the data reproduced in Table 5 below, the sleeved gastric residence systems took about an additional 6-7 minutes to deploy in both a pH 7.0 environment (i.e., esophageal) and a pH 3.0 environment (i.e., gastric). The sleeve that was used for the sleeved gastric residence systems was a size 0 VCaps® Plus HPMC. The testing was performed according to the techniques discussed in detail further below.
  • Example 5 Two different anti-tacking agents, talc and magnesium stearate, were tested for static coefficient of friction and deployment time Twenty two weight percent talc to total solids was used and 4.6 wt. % magnesium stearate to total solids was used. The reverse-enteric, low-friction static coefficient polymer coatings tested may help increase slipperiness of a dosage form when used to coat the capsule. Anti-tacking agents, and in particular, magnesium stearate, may also help increase the slipperiness of a dosage form by lowering the static coefficient of the dosage form.
  • a more slippery dosage form (i.e., having a lower static coefficient of friction) can help minimize the risk of pill esophagitis.
  • the testing was performed according to the techniques discussed in detail further below. [0243] Further, the static coefficient of friction at two minutes for uncoated VCaps Plus HPMC capsule was 0.35 ⁇ 0.04. However, the static coefficient of friction of VCaps ® Plus HPMC capsule coated with a formulation containing Eudragit E, dibutyl sebacate and magnesium stearate was 0.06 ⁇ 0.01. This data indicates that a reverse-enteric coating of Eudragit E in presence of magnesium stearate and dibutyl sebacate is efficient in reducing friction during swallowing of an HPMC capsule.
  • both the dosage forms having the talc coating and the dosage forms having the magnesium stearate coating have lower static coefficients of friction when moist than the uncoated dosage form, indicating that both talc and magnesium stearate help make the dosage form easier to swallow.
  • both the talc-comprising coating and the magnesium stearate-comprising coating yield acceptable deployment times in both a weakly acidic gastric environment (i.e., 3.0 pH) and an esophageal environment (i.e., pH 7.0).
  • Example 6 Figures 10A and 10B show relationships between gastric residence dosage form deployment time and the total weight of the coating on the dosage form. As shown in both Figures, as the individual coating weight of the gastric residence dosage form increases, so too does the deployment time of the dosage form.
  • the data in both Figure 10A and Figure 10B were obtained by conducting a deployment test at pH 3.0 (i.e., weakly-acidic gastric environment). The details of the deployment test are discussed in more detail below.
  • Example 7 Gastric residence dosage forms were dropped to test how physical impact (e.g., due to processing, transport, etc.) may affect deployment time.
  • Example 8 Coated gastric residence dosage forms according to embodiments provided herein were compared to uncoated gastric residence dosage forms. In particular, the deployment times of coated and uncoated gastric residence dosage forms were tested in aqueous pH 3.0 and aqueous pH 7.0 environments. Figure 10 provides results of this test.
  • the uncoated gastric residence dosage forms were prepared using a VCaps® Plus sleeve and a VCaps® Plus capsule.
  • the coated gastric residence dosage forms were prepared using a VCaps® Plus sleeve, a VCaps® Plus capsule, and were coated with a reverse-enteric coating according to embodiments provided herein.
  • the reverse-enteric coating included magnesium stearate as the anti-tacking agent, Eudragit® E PO as the reverse-enteric polymer, and dibutyl sebacate as the plasticizer.
  • the reverse-enteric coating did not include a hydration aid.
  • the deployment test was conducted with a lactate buffer; further details of the deployment test are provided below. [0249] As shown in Figure 11, the deployment times for the coated gastric residence dosage forms at both an aqueous pH 3.0 environment and an aqueous pH 7.0 environment were greater than the deployment time of the uncoated gastric residence dosage form at an aqueous pH 3.0 environment.
  • Example 9 Two types of gelatin shell formulations were evaluated for enrobing gastric residence systems. The components of the two formulations are provided in Table 8, below. The key difference in the two formulations was their bloom strength and the presence of a low molecular weight (3-6 kD) gelatin hydrolysate. The low molecular weight gelatin hydrolysate can allow faster hydration. Prior to enrobing, gastric residence systems were folded/encapsulated in four different capsule and sleeve configurations shown in Table 9, below. Enrobing was performed on each of the folded configurations for both gelatin formulations.
  • Table 8 Two gelatin shell formulations used for enrobing gastric residence systems.
  • Sublot C enrobed gastric residence systems exhibit the fastest deployment times for both formulations. All uncoated enrobed gastric residence systems deployed in less than 60 mins at pH 3, except one in Formulation 1--Sublot D. Sublot D took 85 mins to deploy at pH 3. [0252] The deployment time of Sublot C enrobed gastric residence systems was also evaluated at pH 7, which simulates esophageal environment, to assess the pH responsiveness of the enrobing formulations. For both formulations, there was no significant impact of pH on deployment time.
  • coated enrobed gastric residence systems with Formulation 2 show pH responsive behavior for all Sublots.
  • the average deployment time is 36 ⁇ 11 min at pH 3 and 87 ⁇ 12 min at pH 7. This provides a two-fold differential in deployment time at pH 7 compared to pH 3 for this group of gastric residence systems.
  • Such a pH responsive behavior of coated enrobed gastric residence systems can provide sufficient delay at esophageal pH while allowing rapid deployment in the gastric environment.
  • Deployment time is defined as the amount of time it takes a gastric residence system to assume an open configuration.
  • gastric residence dosage forms can be placed in 35 mL of the specified media on a laboratory rocker. Specifically, a 450 mL jar comprising an 80 mm diameter, a 94 mm height, and a
  • polytetrafluoroethylene-lined lid was used. Once the gastric residence dosage form was placed into the jar with the 35 mL media, the jar was sealed, inverted, and immediately placed on the laboratory rocker. The laboratory rocker was set at 30 cycles per minute. [0257] Various media were used depending on the testing conditions desired. In some tests, a phosphate buffered saline solution was used at either a pH of 7.0 (to replicate a human esophageal pH condition) or a pH of 3.0 (to replicate a human gastric weak acidic pH condition).
  • the 7.0 pH solution was prepared by dissolving 1.36 grams of monobasic potassium phosphate, anhydrous, and 8.41 grams of sodium chloride in water and adjusting to pH 7.0 with sodium hydroxide, then diluting to a final volume of 1.0 liters with water.
  • the 3.0 pH solution was prepared by dissolving 1.36 grams of monobasic potassium phosphate, anhydrous, and 8.41 grams of sodium chloride in water and adjusting to pH 3.0 with hydrochloric acid, then diluting to a final volume of 1.0 liters with water.
  • Deployment tests were also conducted using a media of hydrochloric acid (pH 1.5) with sodium chloride to replicate a human gastric strong acidic pH condition. This solution was prepared by dissolving 9.00 grams of sodium chloride in a solution of 1.5 pH
  • Tack on Storage To measure tack, coated capsules were placed in containers and stored for a specified duration (i.e., 1 week to 1 month). Five to ten coated capsules were placed in each container and sealed with a twist-off cap having an integral foil liner. The containers used were 40 cc or 60 cc wide-mouth pharmaceutical round bottles (Drug Plastics Corp.). The coated capsules were held in the containers in a controlled chamber (e.g., humidity, temperature).
  • Friction Test Squares of approximate three inches by three inches were cut from sausage casing (LEM products Smoked Clear Edible Collagen Casing) and soaked in deionized water for at least 30 minutes. One square was cut for each sample to be tested.
  • An Instron tensile testing machine shown in Figure 14A, was used with the static coefficient of friction fixture (standard add-on) and a 10 N load cell. A custom sled was used to hold two capsules oriented horizontally in direct contact with the casing surface.
  • Figures 14B and 14C show the custom sled.
  • a hydrated casing square was laid on the testing surface and flattened by wiping with a rubber scraper from the center to each edge to remove any air bubbles and excess liquid located between the casing and the testing surface.
  • Two capsule samples were inserted into the slots on the custom machined sled.
  • the sled was attached to a nylon cord. The cord was passed through the fixture pulley and up to the hook on the 10 N load cell attached to the Instron crosshead.
  • the sled was placed down on the casing, with only the two capsules contacting the casing, in an orientation such that the direction of movement as axial with respect to the capsules. The sled was let rest in place for a specified amount of time.
  • the sled was let to rest in place for times from 2 to 10 minutes, to reflect various swallowing times.
  • the crosshead was caused to move upward at a speed of 150 mm/min, pulling the sled forward on the testing surface until a travel distance of 15 mm was reached.
  • the peak force which brought the sled in to motion was measured.
  • the static coefficient of friction for each pair of capsules was calculated by dividing the peak force by the normal force exerted by gravity on the sled and capsules (the normal force exerted by gravity on the sled and capsules was determined based on sled and capsule weight).
  • Embodiment 1 A gastric residence dosage form comprising: a gastric residence system in a folded configuration; a capsule encapsulating the gastric residence system in the folded configuration; and a coating on the capsule, wherein the gastric residence dosage form is configured to release the gastric residence system in a stomach of a patient, allowing the gastric residence system to assume an open configuration.
  • Embodiment 3 The gastric residence dosage form of embodiment 2, wherein the first amount of time is at least 1 minute greater than the second amount of time.
  • Embodiment 5 The gastric residence dosage form of embodiment 2 or 4, wherein the gastric residence dosage form allows the gastric residence system to assume the open configuration in at least 30 minutes when exposed to the aqueous pH 7.0 environment.
  • Embodiment 6. The gastric residence dosage form of any of embodiments 1-5, wherein the gastric residence dosage form allows the gastric residence system to assume the open configuration in a third amount of time when exposed to an aqueous pH 3.0
  • Embodiment 7 The gastric residence dosage form of embodiment 6, wherein the third amount of time is at least 15 seconds greater than the fourth amount of time.
  • Embodiment 8 The gastric residence dosage form of embodiment 6 or 7, wherein the gastric residence dosage form allows the gastric residence system to assume the open configuration in less than 30 minutes when exposed to the aqueous pH 3.0 environment.
  • Embodiment 10 The gastric residence dosage form of any of embodiments 1-9, comprising a sleeve, wherein the sleeve surrounds at least a portion of the gastric residence system in the folded configuration.
  • Embodiment 11 The gastric residence dosage form of any of embodiments 1-10, wherein the coating comprises a reverse-enteric polymer.
  • Embodiment 12 The gastric residence dosage form of embodiment 11, wherein the reverse-enteric polymer comprises a polymethacrylate-based polymer.
  • Embodiment 13 The gastric residence dosage form of any of embodiments 1-12, wherein the coating comprises an anti-tacking agent.
  • Embodiment 14 The gastric residence dosage form of embodiment 13, wherein the anti-tacking agent comprises at least one of talc or magnesium stearate.
  • Embodiment 15 The gastric residence dosage form of any of embodiments 1-14, wherein the coating comprises a plasticizer.
  • the plasticizer comprises at least one of triacetin or dibutyl sebacate.
  • Embodiment 19 The gastric residence dosage form of embodiment 18, wherein the hydration aid comprises at least one of a polyvinylpyrrolidone, a vinylpyrrolidone-vinyl acetate copolymer, a polyethylene glycol, mannitol, or hydroxypropyl methylcellulose.
  • Embodiment 20 The gastric residence dosage form of any of embodiments 1-19, wherein the coating comprises from 50 to 95 wt. % reverse-enteric polymer.
  • Embodiment 21 Embodiment 21.
  • Embodiment 22 The gastric residence dosage form of any of embodiments 1-21, wherein the coating comprises from 1 to 20 wt. % plasticizer.
  • Embodiment 23 The gastric residence dosage form of any of embodiments 1-22, wherein the coating comprises from 3 to 35 wt. % hydration aid.
  • Embodiment 24 The gastric residence dosage form of embodiment 10, wherein the sleeve comprises at least one of gelatin, hydroxypropyl methylcellulose, or pullulan.
  • Embodiment 25 Embodiment 25.
  • Embodiment 26 The gastric residence dosage form of any of embodiments 1-25, wherein the gastric residence dosage form is used to treat a patient.
  • Embodiment 27 The gastric residence dosage form of claim 26, wherein the patient is a human.
  • Embodiment 28 A coating for an encapsulated gastric residence system, the coating comprising: 50-95 wt. % reverse-enteric polymer; 3-25 wt. % anti-tacking agent; and 1-20 wt % plasticizer [0293] Embodiment 29.
  • Embodiment 30 The coating of embodiment 29, wherein the coated capsule encapsulates a gastric residence system to form a gastric residence dosage form, wherein the gastric residence dosage form is configured to release the gastric residence system in a stomach of a patient, allowing the gastric residence system to assume an open configuration.
  • Embodiment 31 The coating of any of embodiments 28-30, comprising 5 to 35 wt. % hydration aid.
  • Embodiment 31 wherein the hydration aid comprises at least one of a polyvinylpyrrolidone, a vinylpyrrolidone-vinyl acetate copolymer, a polyethylene glycol, mannitol, or hydroxypropyl methylcellulose.
  • Embodiment 33 The coating of any of embodiments 28-32, wherein the reverse- enteric polymer comprises a polymethacrylate-based polymer.
  • Embodiment 34 The coating of any of embodiments 28-33, wherein the anti- tacking agent comprises at least one of talc or magnesium stearate.
  • Embodiment 35 Embodiment 35.
  • any of embodiments 28-34 wherein the plasticizer comprises a phthalate, a phosphate, a citrate, a tartrate, an adipate, a sebacate, a sulfonamide, a succinate, a glycolate, a glycerolate, a benzoate, a myristate, a polyethylene glycol, a halogenated phenyl, or a poloxamer.
  • the plasticizer comprises at least one of triacetin and dibutyl sebacate.
  • Embodiment 40 The coating of any of embodiments 28-36, wherein the coating is soluble in an aqueous solution.
  • Embodiment 38 The coating of any of embodiments 28-37, wherein the coating is soluble in an organic solution.
  • Embodiment 39 The coating of any of embodiments 30-38, wherein the gastric residence dosage form allows the gastric residence system to assume the open configuration amount of time is greater than a second amount of time for an uncoated gastric residence dosage form comprising an uncoated capsule to allow a gastric residence system to assume an open configuration when the uncoated gastric residence dosage form is exposed to the aqueous pH 7.0 environment.
  • Embodiment 40 Embodiment 40.
  • Embodiment 41 The coating of embodiment 39 or 40, wherein the gastric residence dosage form allows the gastric residence system to assume the open configuration in at least 20 minutes when exposed to the aqueous pH 7.0 environment.
  • Embodiment 42 The coating of any of embodiments any of claims 39-41, wherein the gastric residence dosage form allows the gastric residence system to assume the open configuration in at least 30 minutes when exposed to the aqueous pH 7.0 environment.
  • Embodiment 43 Embodiment 43.
  • Embodiment 46 The coating of any of embodiments 43-45, wherein the gastric residence dosage form allows the gastric residence system to assume the open configuration in less than 15 minutes when exposed to the aqueous pH 3.0 environment.
  • Embodiment 47 A gastric residence dosage form comprising the coating of any of embodiments 30-46, wherein the gastric residence dosage form is used to treat a patient.
  • Embodiment 48 The gastric residence dosage form of embodiment 47, wherein the patient is a human.
  • Embodiment 49 The coating of embodiment 43 or 44, wherein the gastric residence dosage form allows the gastric residence system to assume the open configuration in less than 30 minutes when exposed to the aqueous pH 3.0 environment.
  • a method of making a gastric residence dosage form comprising: encapsulating a gastric residence system in a folded configuration with a capsule; and coating the capsule with a reverse-enteric coating to form a gastric residence dosage form.
  • Embodiment 50 The method of embodiment 49, comprising binding the gastric residence system in the folded configuration with a sleeve prior to encapsulating.
  • Embodiment 51 The method of embodiment 49 or 50, wherein coating the capsule with a reverse-enteric coating comprises pan-coating the capsule.
  • Embodiment 52 The method of any of embodiments 49-51, wherein the reverse- enteric coating comprises a reverse-enteric polymer, an anti-tacking agent, and a plasticizer.
  • Embodiment 53 The method of embodiment 52, wherein the anti-tacking agent comprises at least one of talc or magnesium stearate.
  • Embodiment 54 The method of embodiment 52 or 53, wherein the plasticizer comprises at least one of a phthalate, a phosphate, a citrate, a tartrate, an adipate, a sebacate, a sulfonamide, a succinate, a glycolate, a glycerolate, a benzoate, a myristate, a polyethylene glycol, a halogenated phenyl, or a poloxamer.
  • Embodiment 55 Embodiment 55.
  • Embodiment 56 The method of any of embodiments 49-55, wherein the reverse- enteric coating comprises a hydration aid.
  • Embodiment 57 The method of embodiment 56, wherein the hydration aid comprises at least one of a polyvinylpyrrolidone, a vinylpyrrolidone-vinyl acetate copolymer, a polyethylene glycol, mannitol, or hydroxypropyl methylcellulose.
  • Embodiment 58 Embodiment 58.
  • Embodiment 60 The method of any of embodiments 49-59, wherein the gastric residence dosage form is configured to release the gastric residence system in a stomach of a patient, allowing the gastric residence system to assume an open configuration.
  • Embodiment 61 The method of any of embodiments 49-57, wherein the capsule comprises at least one of gelatin, hydroxypropyl methylcellulose, or pullulan.
  • Embodiment 64 The method of any of embodiments 60-63, wherein the gastric residence dosage form allows the gastric residence system to assume the open configuration in at least 30 minutes when exposed to the aqueous pH 7.0 environment.
  • Embodiment 65 The method of any of embodiments 60-63, wherein the gastric residence dosage form allows the gastric residence system to assume the open configuration in at least 30 minutes when exposed to the aqueous pH 7.0 environment.
  • Embodiment 65 or 66 wherein the gastric residence dosage form allows the gastric residence system to assume the open configuration in less than 30 minutes when exposed to the aqueous pH 3.0 environment.
  • Embodiment 68 The method of any of embodiments 65-67, wherein the gastric residence dosage form allows the gastric residence system to assume the open configuration in less than 15 minutes when exposed to the aqueous pH 3.0 environment.
  • Embodiment 69 A gastric residence dosage form made using the method of any of embodiments 49-68, wherein the gastric residence dosage form is used to treat a patient.
  • Embodiment 70 The gastric residence dosage form of embodiment 69, wherein the patient is a human.
  • Embodiment 71 A coated dosage form comprising: a dosage form; and a coating comprising a reverse-enteric polymer coating the dosage form, wherein
  • Embodiment 72 The coated dosage form of embodiment 71, wherein the coating comprises magnesium stearate.
  • Embodiment 73 The coated dosage form of embodiment 71 or 72, wherein the dosage form comprises one of a tablet, a capsule, or an enrobed gastric residence system.
  • Embodiment 74 The coated dosage form of embodiment 73, wherein the dosage form comprises a capsule.
  • Embodiment 75 The coated dosage form of claim 74, wherein the capsule encapsulates a gastric residence system.
  • Embodiment 76 The coated dosage form of any of embodiments 71-75, wherein a static coefficient of friction of the coated dosage form is less than 0.3.
  • Embodiment 77 The coated dosage form of embodiment 71-76, wherein the static coefficient of friction of the coated dosage form is less than 0.2.
  • Embodiment 78 The coated dosage form of embodiment 71-77, wherein the static coefficient of friction of the coated dosage form is less than 0.1.
  • Embodiment 79 The coated dosage form of any of embodiments 71-78, wherein
  • Embodiment 80 The coated dosage form of any of embodiments 71-79, wherein the static coefficient of friction is at least 0.08 less than that of an uncoated dosage form.
  • Embodiment 81 The coated dosage form of any of embodiments 71-80, wherein the static coefficient of friction of the coated dosage form is at least 0.15 less than that of an uncoated dosage form.
  • Embodiment 82 The coated dosage form of any of embodiments 71-81, wherein the static coefficient of friction of the coated dosage form is at least 0.2 less than that of an uncoated dosage form.
  • Embodiment 83 Embodiment 83.
  • the coated dosage form of any of embodiments 71-83,the coating comprises 10 to 50 wt. % reverse-enteric polymer.
  • the coated dosage form of any of embodiments 71-84, wherein the coating comprises an anti-tacking agent.
  • Embodiment 86 The coated dosage form of any of embodiments 71-85, wherein the anti-tacking agent comprises talc.
  • the coated dosage form of embodiments 85 or 86, the coating comprises 5 to 30 wt.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
PCT/US2020/023704 2019-03-20 2020-03-19 Capsules and capsule coatings for gastric residence dosage forms Ceased WO2020191229A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CN202080034334.4A CN113966216A (zh) 2019-03-20 2020-03-19 用于胃滞留剂型的胶囊和胶囊衣层
EP20774505.0A EP3941445A4 (en) 2019-03-20 2020-03-19 CAPSULES AND CAPSULE COATINGS FOR GASOLINE DOSAGE FORMS
BR112021018496A BR112021018496A2 (pt) 2019-03-20 2020-03-19 Cápsulas e revestimento de cápsula para formas de dosagem de residência gástrica
US17/593,436 US12447130B2 (en) 2019-03-20 2020-03-19 Capsules and capsule coatings for gastric residence dosage forms
CN202411107403.6A CN119033720A (zh) 2019-03-20 2020-03-19 用于胃滞留剂型的胶囊和胶囊衣层
IL286512A IL286512B2 (en) 2019-03-20 2020-03-19 Capsules and capsule coatings for stomach-retaining dosage forms
CA3134049A CA3134049A1 (en) 2019-03-20 2020-03-19 Capsules and capsule coatings for gastric residence dosage forms
MX2021011314A MX2021011314A (es) 2019-03-20 2020-03-19 Capsulas y recubrimientos de capsulas para formas de dosificacion de residencia gastrica.
JP2021556484A JP2022525926A (ja) 2019-03-20 2020-03-19 胃内滞留剤形用のカプセル及びカプセルコーティング
AU2020240108A AU2020240108B2 (en) 2019-03-20 2020-03-19 Capsules and capsule coatings for gastric residence dosage forms
MX2025012985A MX2025012985A (es) 2019-03-20 2021-09-17 Capsulas y recubrimientos de capsulas para formas de dosificacion de residencia gastrica
JP2025005892A JP2025066761A (ja) 2019-03-20 2025-01-16 胃内滞留剤形用のカプセル及びカプセルコーティング
US19/262,609 US20250332111A1 (en) 2019-03-20 2025-07-08 Capsules and capsule coatings for gastric residence dosage forms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962821352P 2019-03-20 2019-03-20
US62/821,352 2019-03-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US17/593,436 A-371-Of-International US12447130B2 (en) 2019-03-20 2020-03-19 Capsules and capsule coatings for gastric residence dosage forms
US19/262,609 Division US20250332111A1 (en) 2019-03-20 2025-07-08 Capsules and capsule coatings for gastric residence dosage forms

Publications (1)

Publication Number Publication Date
WO2020191229A1 true WO2020191229A1 (en) 2020-09-24

Family

ID=72519175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/023704 Ceased WO2020191229A1 (en) 2019-03-20 2020-03-19 Capsules and capsule coatings for gastric residence dosage forms

Country Status (10)

Country Link
US (2) US12447130B2 (enExample)
EP (1) EP3941445A4 (enExample)
JP (2) JP2022525926A (enExample)
CN (2) CN119033720A (enExample)
AU (1) AU2020240108B2 (enExample)
BR (1) BR112021018496A2 (enExample)
CA (1) CA3134049A1 (enExample)
IL (1) IL286512B2 (enExample)
MX (2) MX2021011314A (enExample)
WO (1) WO2020191229A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12142158B2 (en) 2018-12-03 2024-11-12 Lyndra Therapeutics, Inc. Stomach simulating device
US12144894B2 (en) 2020-07-29 2024-11-19 The Secant Group, Llc Shape-guided controlled release and retention with structures including crosslinked poly(glycerol sebacate)
US12447130B2 (en) 2019-03-20 2025-10-21 Lyndra Therapeutics, Inc. Capsules and capsule coatings for gastric residence dosage forms
US12582608B2 (en) 2019-03-20 2026-03-24 Nortiva Bio, Inc. Coatings for gastric residence dosage forms

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120091832A (zh) * 2022-08-03 2025-06-03 林德拉治疗公司 用于胃驻留系统的金属芯部

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050064027A1 (en) * 2001-12-15 2005-03-24 Spherics, Inc. Bioadhesive drug delivery system with enhanced gastric retention
WO2007002518A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
US20110091542A1 (en) * 2008-12-04 2011-04-21 Intec Pharma Ltd. Baclofen and r-baclofen gastroretentive drug delivery systems
US9737905B2 (en) * 2012-08-29 2017-08-22 Cardiac Pacemakers, Inc. Enhanced low friction coating for medical leads and methods of making
WO2018064630A1 (en) * 2016-09-30 2018-04-05 Lyndra, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706149D0 (en) 1997-03-25 1997-05-14 Scherer Corp R P Comestible capsules having flavoured coatings
DK1578350T3 (da) 2002-03-26 2009-08-10 Euro Celtique Sa Sammensætninger med gel-coating med depotvirkning
IL166183A0 (en) * 2005-01-06 2006-01-15 Yissum Res Dev Co Novel diagnostic and imaging techniques of the gi tract
KR20080005429A (ko) 2005-04-19 2008-01-11 알자 코포레이션 트라마돌 및 가바펜틴을 포함하는 물질의 배합물
JP4948828B2 (ja) 2005-11-28 2012-06-06 森下仁丹株式会社 胃内浮遊滞留シームレスカプセルとその製造方法
CA2675230A1 (en) 2006-01-10 2008-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
EP2997953B1 (en) 2006-01-18 2018-12-26 Intec Pharma Ltd. Delivery device for oral intake of an agent
WO2007093999A1 (en) 2006-02-15 2007-08-23 Intec Pharma Ltd. A gastro-retentive system for the delivery of macromolecules
JP2012500230A (ja) 2008-08-18 2012-01-05 北京天衡▲薬▼物研究院 胃内滞留薬物放出システム及びその製造方法と使用
US8006033B2 (en) 2008-09-09 2011-08-23 Intel Corporation Systems, methods, and apparatuses for in-band data mask bit transmission
US20100286628A1 (en) * 2009-05-07 2010-11-11 Rainbow Medical Ltd Gastric anchor
US8414559B2 (en) * 2009-05-07 2013-04-09 Rainbow Medical Ltd. Gastroretentive duodenal pill
EP2490677A2 (en) * 2009-10-19 2012-08-29 Intec Pharma Ltd. Novel gastroretentive dosage forms of poorly soluble drugs
CA2825917C (en) 2011-02-14 2016-08-30 The Procter & Gamble Company Filmcoated solid dosage forms comprising honey in the coating
WO2015187746A1 (en) 2014-06-02 2015-12-10 Teva Pharmaceutical Industries Ltd. Expandable gastroretentive dosage form
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
NZ727659A (en) 2014-06-11 2021-12-24 Massachusetts Inst Technology Residence structures and related methods
WO2015195989A1 (en) 2014-06-20 2015-12-23 Banner Life Sciences Llc Enteric soft capsule compositions
EP3288604B1 (en) 2015-05-01 2021-11-17 Massachusetts Institute of Technology Triggerable shape memory induction devices
MX387092B (es) 2015-06-17 2025-03-19 Biogen Ma Inc Particulas de dimetilfumarato y composiciones farmaceuticas de estas.
US20190000768A1 (en) 2015-08-04 2019-01-03 Fuji Capsule Co., Ltd. Enteric capsule
US11576859B2 (en) 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
WO2017100367A1 (en) 2015-12-08 2017-06-15 Lyndra, Inc. Geometric configurations for gastric residence systems
CN109310639A (zh) 2016-05-27 2019-02-05 林德拉有限公司 用于胃驻留系统的材料结构
CN110035718B (zh) * 2016-12-02 2021-04-06 克雷西奥生物科技有限公司 胃内滞留系统
CA3066658A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
US11793751B2 (en) 2017-09-20 2023-10-24 Lyndra Therapeutics, Inc. Encapsulation of gastric residence systems
CN111587088A (zh) * 2017-11-28 2020-08-25 麻省理工学院 胃驻留电子装置
JP2021535090A (ja) 2018-08-15 2021-12-16 リンドラ セラピューティクス， インコーポレイティド 治療薬物の腸内送達のためのシステム
WO2020117855A1 (en) 2018-12-03 2020-06-11 Lyndra, Inc. Stomach simulating device
AU2020242062B2 (en) 2019-03-20 2025-12-11 Nortiva Bio, Inc. Coatings for gastric residence dosage forms
BR112021018496A2 (pt) 2019-03-20 2021-11-30 Lyndra Therapeutics Inc Cápsulas e revestimento de cápsula para formas de dosagem de residência gástrica
MX2022005494A (es) 2019-11-08 2022-08-11 Lyndra Therapeutics Inc Sistemas de residencia gastrica para la administracion de agentes activos.
JP2022553867A (ja) 2019-11-08 2022-12-26 リンドラ セラピューティクス， インコーポレイティド 胃内滞留を改善するフィラメントを有する胃内滞留システム
IL292848A (en) 2019-11-08 2022-07-01 Lyndra Therapeutics Inc Polymeric linkers for a gastric residence system
US20220387312A1 (en) 2019-11-08 2022-12-08 Lyndra Therapeutics, Inc. Gastric residence systems having arms with controlled stiffness for improved gastric residence
WO2021092486A1 (en) 2019-11-08 2021-05-14 Lyndra, Inc. Formulations for release-rate modulating films for gastric residence systems
US20240390270A1 (en) 2021-01-19 2024-11-28 Lyndra Therapeutics, Inc. Gastric residence systems for administration of risperidone
JP2024517829A (ja) 2021-05-05 2024-04-23 リンドラ セラピューティクス， インコーポレイティド メタドンを含む胃内滞留システム
WO2022236288A1 (en) 2021-05-05 2022-11-10 Lyndra Therapeutics, Inc. Gastric residence systems comprising buprenorphine and naloxone
AU2023209872A1 (en) 2022-01-19 2024-08-01 Nortiva Bio, Inc. Dosage forms for gastric retention
CN120091832A (zh) 2022-08-03 2025-06-03 林德拉治疗公司 用于胃驻留系统的金属芯部
JP2025531626A (ja) 2022-09-30 2025-09-22 リンドラ セラピューティクス， インコーポレイティド 胃内滞留システムを用いたリスペリドンの投与レジメン
US20240398701A1 (en) 2023-06-02 2024-12-05 Lyndra Therapeutics, Inc. Manufacturing methods for gastric residence systems

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050064027A1 (en) * 2001-12-15 2005-03-24 Spherics, Inc. Bioadhesive drug delivery system with enhanced gastric retention
WO2007002518A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
US20110091542A1 (en) * 2008-12-04 2011-04-21 Intec Pharma Ltd. Baclofen and r-baclofen gastroretentive drug delivery systems
US9737905B2 (en) * 2012-08-29 2017-08-22 Cardiac Pacemakers, Inc. Enhanced low friction coating for medical leads and methods of making
WO2018064630A1 (en) * 2016-09-30 2018-04-05 Lyndra, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3941445A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12142158B2 (en) 2018-12-03 2024-11-12 Lyndra Therapeutics, Inc. Stomach simulating device
US12447130B2 (en) 2019-03-20 2025-10-21 Lyndra Therapeutics, Inc. Capsules and capsule coatings for gastric residence dosage forms
US12582608B2 (en) 2019-03-20 2026-03-24 Nortiva Bio, Inc. Coatings for gastric residence dosage forms
US12144894B2 (en) 2020-07-29 2024-11-19 The Secant Group, Llc Shape-guided controlled release and retention with structures including crosslinked poly(glycerol sebacate)

Also Published As

Publication number Publication date
CA3134049A1 (en) 2020-09-24
CN119033720A (zh) 2024-11-29
IL286512B1 (en) 2025-11-01
JP2022525926A (ja) 2022-05-20
EP3941445A1 (en) 2022-01-26
IL286512B2 (en) 2026-03-01
US20250332111A1 (en) 2025-10-30
AU2020240108B2 (en) 2025-12-04
MX2021011314A (es) 2021-12-10
EP3941445A4 (en) 2023-08-02
BR112021018496A2 (pt) 2021-11-30
US12447130B2 (en) 2025-10-21
IL286512A (en) 2021-10-31
CN113966216A (zh) 2022-01-21
AU2020240108A1 (en) 2021-11-11
US20220160642A1 (en) 2022-05-26
MX2025012985A (es) 2025-12-01
JP2025066761A (ja) 2025-04-23

Similar Documents

Publication Publication Date Title
AU2020240108B2 (en) Capsules and capsule coatings for gastric residence dosage forms
US12582608B2 (en) Coatings for gastric residence dosage forms
JP2022525926A5 (enExample)
US9579293B2 (en) Timed, pulsatile release systems
RU2428176C2 (ru) Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты
EP2844296B1 (en) Aqueous dispersions of hydroxypropyl methylcellulose acetate succinate (hpmcas)
JP2022525482A5 (enExample)
CN101686947A (zh) 度洛西汀制剂
HK40066247A (en) Coatings for gastric residence dosage forms
HK40066247B (en) Coatings for gastric residence dosage forms
WO2010078878A1 (en) Duloxetine formulations
AU2013273835B2 (en) Timed, pulsatile release systems

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20774505

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021556484

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3134049

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2021/011314

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021018496

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020774505

Country of ref document: EP

Effective date: 20211020

ENP Entry into the national phase

Ref document number: 2020240108

Country of ref document: AU

Date of ref document: 20200319

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112021018496

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210917

WWP Wipo information: published in national office

Ref document number: MX/A/2021/011314

Country of ref document: MX

WWG Wipo information: grant in national office

Ref document number: 17593436

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: MX/A/2021/011314

Country of ref document: MX

WWG Wipo information: grant in national office

Ref document number: 286512

Country of ref document: IL